Staidson BioPharma Inc. in San Francisco is a subsidiary of Staidson (Beijing) Biopharmaceutical Company Ltd.. Staidson (Beijing) was established in 2002 in the Beijing Economic and Technology Development Area (BDA). Finished its IPO on April 15, 2011 at Growth Enterprise Market in Shenzhen Stock Market, China (No. 300204). Currently we have employee 830 totals, 150 for R&D and 430 for Sales and marketing. Five products have been approved for Chinese market, including Patent biological medicine, chemical medicine, and generic chemical drug. We are looking for License-in opportunity for new biological product and technologies for Chinese marketing or co-development globally.